Literature DB >> 367555

Hypercalcemia and cancer: an update.

T M Murray, R G Josse, J N Heersche.   

Abstract

Hypercalcemia is a not infrequent complication of cancer that every physician should be aware of. It is a significant factor in the morbidity and mortality of cancer patients. Almost invariably hypercalcemia is associated with accelerated resorption of bone, which is thought to be mediated by humoral or metabolic factors. Three such factors, parathyroid hormone, E2 prostaglandins and osteoclast activating factor, have been strongly implicated in the pathogenesis of hypercalcemia in cancer patients. Other mechanisms for the hypercalcemia may exist. Accurate diagnosis of the disorder is important in therapy, and current research into the various mechanisms for hypercalcemia in cancer patients may well lead to new modes of therapy that are more specific and perhaps less toxic.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 367555      PMCID: PMC1819098     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  47 in total

1.  Prostaglandin-mediated hypercalcemia in the VX2 carcinoma-bearing rabbit.

Authors:  H W Seyberth; W C Hubbard; O Oelz; B J Sweetman; J T Watson; J A Oates
Journal:  Prostaglandins       Date:  1977-08

2.  In vitro osteolysis by human breast tumours.

Authors:  G C Easty; M Dowsett; T J Powles; D M Easty; J C Gazet; A M Neville
Journal:  Proc R Soc Med       Date:  1977-03

3.  Characterization of the group of patients with the hypercalcemia of cancer who respond to treatment with prostaglandin synthesis inhibitors.

Authors:  H W Seyberth; G V Segre; P Hamet; B J Sweetman; J T Potts; J A Oates
Journal:  Trans Assoc Am Physicians       Date:  1976

4.  Big and little forms of osteoclast activating factor.

Authors:  G R Mundy; L G Raisz; J L Shapiro; J G Bandelin; R J Turcotte
Journal:  J Clin Invest       Date:  1977-07       Impact factor: 14.808

5.  Effect of prostaglaidin endoperoxides and metabolites on bone resorption in vitro.

Authors:  L G Raisz; J W Dietrich; H A Simmons; H W Seyberth; W Hubbard; J A Oates
Journal:  Nature       Date:  1977-06-09       Impact factor: 49.962

6.  Parathyroid hormone inhibitors. Design, synthesis, and biologic evaluation of hormone analogues.

Authors:  M Rosenblatt; E N Callahan; J E Mahaffey; A Pont; J T Potts
Journal:  J Biol Chem       Date:  1977-08-25       Impact factor: 5.157

7.  Differential diagnosis of hypercalcemia and cancer.

Authors:  W P Myers
Journal:  CA Cancer J Clin       Date:  1977 Sep-Oct       Impact factor: 508.702

8.  Calcium metabolism in cancer. Studies using calcium isotopes and immunoassays for parathyroid hormone and calcitonin.

Authors:  R S Coombes; M K Ward; P B Greenberg; C J Hillyard; B R Tulloch; R Morrison; G F Joplin
Journal:  Cancer       Date:  1976-11       Impact factor: 6.860

9.  Plasma prostaglandins in hypercalcemic patients with neoplastic disease.

Authors:  L M Demers; J C Allegra; H A Harvey; A Lipton; J R Luderer; R Mortel; D E Brenner
Journal:  Cancer       Date:  1977-04       Impact factor: 6.860

10.  Secretion of prostaglandins as bone-resorbing agents by renal cortical carcinoma in culture.

Authors:  D Atkins; K J Ibbotson; K Hillier; N H Hunt; J C Hammonds; T J Martin
Journal:  Br J Cancer       Date:  1977-11       Impact factor: 7.640

View more
  2 in total

1.  Recognizing hyperparathyroidism.

Authors:  T M Murray; R G Josse
Journal:  Can Med Assoc J       Date:  1982-05-01       Impact factor: 8.262

Review 2.  [Hypocalcemia in malignant diseases].

Authors:  E Heidbreder; K Schafferhans; A Heidland
Journal:  Klin Wochenschr       Date:  1983-08-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.